データなし
データなし
CEL-SCI Announced Multikine Demonstrates Tumor Regression Pre-Surgery In 3 Weeks; FDA Approves 212-Person Study With 73% Survival Rate Vs. 45% Control In Head And Neck Cancer
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
Watching CEL-SCI; Zacks Small-Cap Research Gives Stock $7 Price Valuation
CEL-SCI, FDA Agree on Phase 3 Trial Design for Cancer Drug
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
CEL-SCI Announces The Potential Impact On The Clinical Development Of Its Immunotherapy Multikine Resulting From A Recent U.S. FDA Oncologic Drugs Advisory Committee Meeting; Multikine Has Shown Survival Benefit And Favorable Safety Profile In A...